Drug intelligence / Profile preview

OROFLOW

Development stage: Preclinical
Lead developer: LTR Pharma
Modality: Small Molecules
Administration: Intranasal

Overview

OROFLOW is a novel intranasal small molecule spray being developed by LTR Pharma in collaboration with Strategic Drug Solutions (SDS) for the treatment of Oesophageal Motility Disorders (OMD) and associated dysphagia (swallowing difficulties). The product utilizes LTR Pharma's proprietary nasal delivery platform, which is designed to facilitate rapid absorption and provide symptom relief within approximately 10 minutes. OROFLOW is intended to serve as a non-invasive therapeutic alternative to current standard-of-care treatments such as surgery, botulinum toxin injections, and pneumatic dilation. As of May 2025, the specific active pharmaceutical ingredient has not been publicly disclosed.

Brand names: OROFLOW

Beyond the preview

Go deeper on OROFLOW.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OROFLOW.

Explore the full profile